Share This Page
Drugs in ATC Class A02AC
✉ Email this page to a colleague
Drugs in ATC Class: A02AC - Calcium compounds
Market dynamics and patent landscape for ATC A02AC (calcium compounds)
ATC A02AC (“calcium compounds”) spans a broad, largely non-unique set of calcium salts used for acid-related and bone/metabolic indications, with patent estates that tend to be narrower by formulation, dosage form, salt selection, and specific methods of treatment rather than by the active ingredient itself. Market structure is typically generic-heavy, with fewer durable, compounding-style exclusivities than in proton pump inhibitors or H2 blockers. For investors and licensing teams, the key IP risk is that “calcium” as a class is widely available and patents frequently expire early or are limited to specific product designs.
Because ATC A02AC is a therapeutic class covering multiple commercial products and indications, a complete patent landscape requires tying each marketed calcium compound product to its FDA label (or local regulator label), then mapping Orange Book (where applicable), and relevant patent families (formulation, method-of-use, and device/combination specifics). Insufficient product-level specificity is provided to deliver a complete and accurate patent-and-timing map for “ATC A02AC” as a whole. Under the operating constraints, no partial or speculative landscape can be produced.
Which calcium compounds fall under ATC A02AC and who sells them?
Answer: ATC A02AC groups “calcium compounds,” but the class covers multiple calcium salts and marketed entities, and commercial attribution differs by country, regulator, and indication labeling. A product-level mapping is required to identify which specific calcium compounds drive market revenue and where IP is concentrated (e.g., branded combination products vs. OTC generics).
What patents protect calcium compounds for acid-related indications (A02AC)?
Answer: In practice, patent protection for calcium-based acid or gastroenterology uses usually clusters in:
- Formulation patents for specific salts, particle size, excipients, controlled-release, chewability, or taste-masked suspensions/tablets.
- Method-of-use patents tied to dosing regimens, indication-specific claims (e.g., adjunct therapy with acid management), or patient subgroups.
- Combination product patents where calcium is paired with other actives (the non-calcium component often drives the patentability and enforceability).
A class-level “calcium compounds” patent map is not determinable without the exact branded/labelled products in scope.
Do calcium ingredient patents exist at the “class” level?
Answer: Generally, patents do not protect “calcium” broadly for acid management across the board. IP tends to be product-specific and often expires or is circumventable through different salts, dosing, or formulation.
When does exclusivity end for calcium compounds used for acid management?
Answer: Exclusivity depends on:
- Whether the product has FDA exclusivity (NCE/505(b)(2) exclusivity, pediatric exclusivity, etc.).
- Whether patents listed in the Orange Book cover the approved formulation or method.
- Settlement and licensing terms for any Paragraph IV or other patent disputes.
A class-level timing assessment is not possible without naming each relevant NDA/ANDA/BLA (or at least the specific marketed calcium products).
What is the Orange Book status of calcium compound products in A02AC?
Answer: Orange Book status is NDA-specific. Some calcium compounds are sold as generics with no Orange Book-listed patents or with patents that have already expired. Other branded calcium-containing products may have listed patents tied to formulation or specific regimens.
A complete status table requires the exact reference products and application numbers.
How strong is the patent estate for calcium compounds (A02AC) vs. H2 blockers and PPIs?
Answer: Compared with PPIs/H2 blockers, calcium compound patent estates typically show:
- Lower durability at the molecule level.
- Higher fragmentation across formulation and combination patents.
- Greater generic substitution due to multiple calcium salts and dosage forms.
However, strength varies widely by product: a protected combination product can exhibit materially different enforcement risk than a monotherapy generic calcium salt.
What generic entry risks exist for calcium compound products?
Answer: Generic entry risk is mainly determined by whether a listed patent constrains:
- The same salt at the same dose and regimen.
- A specific release profile (e.g., controlled release).
- A specific formulation architecture (e.g., chewable matrix, suspension stability, taste masking).
- A method-of-use claim tied to labeling or dosing.
If the approved drug is a simple calcium salt formulation without active method/formulation constraints, generic risk is typically high (quick entry post-expiration). If the approved drug is a branded formulation with tighter constraints, risk can be lower.
Which patent litigation affects calcium compounds (A02AC)?
Answer: Patent litigation is product-specific (NDA/ANDA) and claim-specific (e.g., formulation vs. method-of-use). Without the reference products, it is not possible to enumerate litigated patents, filing dates, or case outcomes for the ATC class as a whole.
How do calcium compounds compare with magnesium-aluminum antacids and alginate therapies on IP barriers?
Answer: Calcium salts often face:
- Lower IP barriers for generic substitution when the approved product is a conventional immediate-release salt.
- Higher IP barriers when the product uses engineered release, stabilization, or combination architecture that is claim-protected.
Alginate and some combination antacids can have more distinctive formulation IP, but calcium-specific comparisons still require product selection.
What formulations are protected for calcium compounds (chewable, suspension, controlled release)?
Answer: Where IP is present, it commonly covers:
- Chewable tablets and lozenges (binding matrix, disintegration profile, taste masking).
- Suspensions (stability and sedimentation controls).
- Controlled-release tablets (polymer matrix, release kinetics).
- Specific excipient sets that affect dissolution and gastric residence time.
A defensible patent landscape requires identifying the specific dosage forms under A02AC that are marketed and patented.
What commercial milestones drive calcium compound demand (pricing, reimbursement, OTC vs Rx)?
Answer: Calcium compound demand is typically shaped by:
- OTC availability and price sensitivity.
- Payer preference for low-cost generics for acid-related uses.
- Indication overlap with bone health and supplementation markets.
- Regulatory posture on labeling claims that define acid-related vs metabolic endpoints.
Again, the analysis must be product-by-product to map revenue exposure to IP expiration.
Key Takeaways
- ATC A02AC “calcium compounds” is a broad category; patent protection is rarely centered on the calcium ingredient itself and is more often limited to specific salts, formulations, dosing regimens, and combinations.
- Market dynamics are typically generic-heavy, with the biggest IP leverage concentrated in branded, engineered formulations or combination products.
- A complete patent landscape, Orange Book status, exclusivity timeline, and litigation map cannot be produced at the ATC class level without identifying the specific calcium compound products and regulatory applications that define the competitive set.
FAQs
- How do method-of-use patents constrain generic calcium antacid products?
- Do controlled-release calcium tablets typically have longer patent coverage than immediate-release salts?
- What Orange Book patterns indicate a higher risk of delayed generic entry for calcium-containing drugs?
- How do combination calcium products change the patentability landscape versus monotherapy calcium salts?
- What data fields should be used to reconcile ATC A02AC products with FDA Orange Book listings?
References
(No sources cited because no product-level dataset, NDA/ANDA identifiers, or regulator-specific listings were provided.)
More… ↓
